title: Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
abstract: We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors for the achievement of complete cytogenetic responses on third-line therapy. Younger age and the achievement of a cytogenetic response on second line were the only independent predictors for overall survival (OS). At 3 months, the 9 patients who had achieved a cytogenetic response had better 30-month probabilities of complete cytogenetic responses and OS than the patients who had failed to do so. Factors measurable before starting treatment with third line therapy and cytogenetic responses at 3 months can accurately predict subsequent outcome and thus guide clinical decisions.
authors.affiliation: Department of Haematology, Imperial College London, London, UK.
authors.forename: Amr R
authors.initials: AR
authors.lastname: Ibrahim
authors.forename: Christos
authors.initials: C
authors.lastname: Paliompeis
authors.forename: Marco
authors.initials: M
authors.lastname: Bua
authors.forename: Dragana
authors.initials: D
authors.lastname: Milojkovic
authors.forename: Richard
authors.initials: R
authors.lastname: Szydlo
authors.forename: Jamshid S
authors.initials: JS
authors.lastname: Khorashad
authors.forename: Letizia
authors.initials: L
authors.lastname: Foroni
authors.forename: Alistair
authors.initials: A
authors.lastname: Reid
authors.forename: Hugues
authors.initials: H
authors.lastname: de Lavallade
authors.forename: Katayoun
authors.initials: K
authors.lastname: Rezvani
authors.forename: Francesco
authors.initials: F
authors.lastname: Dazzi
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: John M
authors.initials: JM
authors.lastname: Goldman
authors.forename: David
authors.initials: D
authors.lastname: Marin
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D015331:Cohort Studies; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage; D012074:Remission Induction; D016879:Salvage Therapy; D013844:Thiazoles / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib